Top

Published in:

Open Access 01-11-2017 | Therapy in Practice

Aspirin for Prevention of Preeclampsia

Authors: A. Atallah, E. Lecarpentier, F. Goffinet, M. Doret-Dion, P. Gaucherand, V. Tsatsaris

Published in: Drugs | Issue 17/2017

Abstract

Aspirin is currently the most widely prescribed treatment in the prevention of cardiovascular complications. The indications for the use of aspirin during pregnancy are, however, the subject of much controversy. Since the first evidence of the obstetric efficacy of aspirin in 1985, numerous studies have tried to determine the effect of low-dose aspirin on the incidence of preeclampsia, with very controversial results. Large meta-analyses including individual patient data have demonstrated that aspirin is effective in preventing preeclampsia in high-risk patients, mainly those with a history of preeclampsia. However, guidelines regarding the usage of aspirin to prevent preeclampsia differ considerably from one country to another. Screening modalities, target population, and aspirin dosage are still a matter of debate. In this review, we report the pharmacodynamics of aspirin, its main effects according to dosage and gestational age, and the evidence-based indications for primary and secondary prevention of preeclampsia.

Gaspoz J-M, Coxson PG, Goldman PA, et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med. 2002;346:1800–6. doi:10.1056/NEJM200206063462309.CrossRefPubMed

Cadavid AP. Aspirin: the mechanism of action revisited in the context of pregnancy complications. Front Immunol. 2017;8:261. doi:10.3389/fimmu.2017.00261.CrossRefPubMedPubMedCentral

Kattah AG, Garovic VD. The management of hypertension in pregnancy. Adv Chronic Kidney Dis. 2013;20:229–39. doi:10.1053/j.ackd.2013.01.014.CrossRefPubMedPubMedCentral

Bergel E, Carroli G, Althabe F. Ambulatory versus conventional methods for monitoring blood pressure during pregnancy. Cochrane Database Syst Rev 2002:CD001231. doi:10.1002/14651858.CD001231.

Askie LM, Duley L, Henderson-Smart DJ, Stewart LA. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. The Lancet. 2007;369:1791–8. doi:10.1016/S0140-6736(07)60712-0.CrossRef

Woelkers D, Barton J, von Dadelszen P, Sibai B. The revised 2013 ACOG definitions of hypertensive disorders of pregnancy significantly increase the diagnostic prevalence of preeclampsia. Pregnancy Hypertens Int J Womens Cardiovasc Health. 2015;5:38. doi:10.1016/j.preghy.2014.10.075.

Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33:130–7. doi:10.1053/j.semperi.2009.02.010.CrossRefPubMed

von Dadelszen P, Magee LA. Pre-eclampsia: an update. Curr Hypertens Rep. 2014;16:1–14. doi:10.1007/s11906-014-0454-8.

Say L, Chou D, Gemmill A, Tunçalp Ö, Moller A-B, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014;2:e323–33. doi:10.1016/S2214-109X(14)70227-X.CrossRefPubMed

10.

Lafont O. From the willow to aspirin. Rev Hist Pharm. 2007;55:209–16.CrossRef

11.

Botting RM. Vane’s discovery of the mechanism of action of aspirin changed our understanding of its clinical pharmacology. Pharmacol Rep PR. 2010;62:518–25.CrossRefPubMed

12.

West GB. Aspirin and the prostaglandins. Chem Drug. 1972;198:196–7.PubMed

13.

Smith WL. The eicosanoids and their biochemical mechanisms of action. Biochem J. 1989;259:315.CrossRefPubMedPubMedCentral

14.

Mitchell JA, Ahmetaj-Shala B, Kirkby NS, Wright WR, Mackenzie LS, Reed DM, et al. Role of prostacyclin in pulmonary hypertension. Glob Cardiol Sci Pract. 2014;2014:382. doi:10.5339/gcsp.2014.53.PubMedPubMedCentral

15.

Maclouf J, Bellucci S. Role of prostaglandins and thromboxanes in cardiovascular physiopathology. Presse Medicale Paris Fr. 1983;1985(14):1603–6.

16.

Bowen RS, Zhang Y, Gu Y, Lewis DF, Wang Y. Increased phospholipase A2 and thromboxane but not prostacyclin production by placental trophoblast cells from normal and preeclamptic pregnancies cultured under hypoxia condition. Placenta. 2005;26:402–9. doi:10.1016/j.placenta.2004.07.007.CrossRefPubMed

17.

Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA. 1993;90:11693–7.CrossRefPubMedPubMedCentral

18.

Lu Y, Wahl LM. Oxidative stress augments the production of matrix metalloproteinase-1, cyclooxygenase-2, and prostaglandin E2 through enhancement of NF-kappa B activity in lipopolysaccharide-activated human primary monocytes. J Immunol Baltim Md. 1950;2005(175):5423–9.

19.

Chiang N, Serhan CN. Aspirin triggers formation of anti-inflammatory mediators: new mechanism for an old drug. Discov Med. 2004;4:470–5.PubMed

20.

Takahashi Y. Molecular structure and regulation of cyclooxygenase. Nihon Rinsho Jpn J Clin Med. 1992;50:259–63.

21.

Trnavský K, Zachar M. Correlation of serum aspirin esterase activity and half-life of salicylic acid. Agents Actions. 1975;5:549–52.CrossRefPubMed

22.

Bojić M, Sedgeman CA, Nagy LD, Guengerich FP. Aromatic hydroxylation of salicylic acid and aspirin by human cytochromes P450. Eur J Pharm Sci Off J Eur Fed Pharm Sci. 2015;73:49–56. doi:10.1016/j.ejps.2015.03.015.

23.

Patrono C, Ciabattoni G, Patrignani P, Pugliese F, Filabozzi P, Catella F, et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation. 1985;72:1177–84.CrossRefPubMed

24.

Patrono C. Aspirin and human platelets: from clinical trials to acetylation of cyclooxygenase and back. Trends Pharmacol Sci. 1989;10:453–8. doi:10.1016/S0165-6147(89)80010-0.CrossRefPubMed

25.

Das UN. COX-2 inhibitors and metabolism of essential fatty acids. Med Sci Monit Int Med J Exp Clin Res. 2005;11:RA233–7.

26.

Patrick J, Dillaha L, Armas D, Sessa WC. A randomized trial to assess the pharmacodynamics and pharmacokinetics of a single dose of an extended-release aspirin formulation. Postgrad Med. 2015;127:573–80. doi:10.1080/00325481.2015.1050341.CrossRefPubMed

27.

Sibai BM, Mirro R, Chesney CM, Leffler C. Low-dose aspirin in pregnancy. Obstet Gynecol. 1989;74:551–7.PubMed

28.

Roberts MS, Joyce RM, McLeod LJ, Vial JH, Seville PR. Slow-release aspirin and prostaglandin inhibition. Lancet Lond Engl. 1986;1:1153–4.CrossRef

29.

Caron N, Rivard G-E, Michon N, Morin F, Pilon D, Moutquin J-M, et al. Low-dose ASA response using the PFA-100 in women with high-risk pregnancy. J Obstet Gynaecol Can JOGC J Obstet Gynecol Can JOGC. 2009;31:1022–7.

30.

Wegert W, Graff J, Kaiser D, Breddin HK, Klinkhardt U, Harder S. Effects of antiplatelet agents on platelet-induced thrombin generation. Int J Clin Pharmacol Ther. 2002;40:135–41.CrossRefPubMed

31.

Basinski A, Naylor CD. Aspirin and fibrinolysis. Lancet Lond Engl. 1988;2:1188–9.CrossRef

32.

Chen Y-H, Lin S-J, Chen Y-L, Liu P-L, Chen J-W. Anti-inflammatory effects of different drugs/agents with antioxidant property on endothelial expression of adhesion molecules. Cardiovasc Hematol Disord Drug Targets. 2006;6:279–304.CrossRefPubMed

33.

Kim J, Lee K-S, Kim J-H, Lee D-K, Park M, Choi S, et al. Aspirin prevents TNF-α-induced endothelial cell dysfunction by regulating the NF-κB-dependent miR-155/eNOS pathway: role of a miR-155/eNOS axis in preeclampsia. Free Radic Biol Med. 2017;104:185–98. doi:10.1016/j.freeradbiomed.2017.01.010.CrossRefPubMed

34.

Doridot L, Passet B, Méhats C, Rigourd V, Barbaux S, Ducat A, et al. Preeclampsia-like symptoms induced in mice by fetoplacental expression of STOX1 are reversed by aspirin treatment. Hypertens Dallas Tex. 1979;2013(61):662–8. doi:10.1161/HYPERTENSIONAHA.111.202994.

35.

Erdemli HK, Yıldırımlar P, Alper TY, Kocabaş R, Salis O, Bedir A. Increased serum heme oxygenase-1 levels as a diagnostic marker of oxidative stress in preeclampsia. Hypertens Pregnancy. 2014;33:488–97. doi:10.3109/10641955.2014.946613.CrossRefPubMed

36.

Ayala DE, Ucieda R, Hermida RC. Chronotherapy with low-dose aspirin for prevention of complications in pregnancy. Chronobiol Int. 2013;30:260–79. doi:10.3109/07420528.2012.717455.CrossRefPubMed

37.

Bonten TN, Saris A, van Oostrom MJ, Snoep JD, Rosendaal FR, Zwaginga J, et al. Effect of aspirin intake at bedtime versus on awakening on circadian rhythm of platelet reactivity. A randomised cross-over trial. Thromb Haemost. 2014;112:1209–18. doi:10.1160/TH14-05-0453.CrossRefPubMed

38.

Walsh SW. Eicosanoids in preeclampsia. Prostaglandins Leukot Essent Fatty Acids. 2004;70:223–32.CrossRefPubMed

39.

Lecarpentier E, Haddad B, Goffinet F, Tsatsaris V. Moyens thérapeutiques de la prise en charge de la pré-éclampsie. Presse Médicale. 2016;. doi:10.1016/j.lpm.2016.04.017.

40.

Mousa AA, Strauss JF, Walsh SW. Reduced methylation of the thromboxane synthase gene is correlated with its increased vascular expression in preeclampsia. Hypertension. 2012;59:1249–55. doi:10.1161/hypertensionaha.111.188730.CrossRefPubMedPubMedCentral

41.

Panagodage S, Yong HE, Da Silva Costa F, Borg AJ, Kalionis B, Brennecke SP, Murthi P. Low-dose acetylsalicylic acid treatment modulates the production of cytokines and improves trophoblast function in an in vitro model of early-onset preeclampsia. Am J Pathol. 2016;186(12):3217–24.CrossRefPubMed

42.

Scazzocchio E, Oros D, Diaz D, Ramirez JC, Ricart M, Meler E, et al. Impact of aspirin on trophoblastic invasion in women with abnormal uterine artery Doppler at 11–14 weeks: a randomized controlled study. Ultrasound Obstet Gynecol Off J Int Soc Ultrasound Obstet Gynecol. 2017;49:435–41. doi:10.1002/uog.17351.CrossRef

43.

Walsh SW. Low-dose aspirin: treatment for the imbalance of increased thromboxane and decreased prostacyclin in preeclampsia. Am J Perinatol. 1989;6:124–32. doi:10.1055/s-2007-999562.CrossRefPubMed

44.

Perneby C, Vahter M, Åkesson A, Bremme K, Hjemdahl P. Thromboxane metabolite excretion during pregnancy – influence of preeclampsia and aspirin treatment. Thromb Res. 2011;127:605–6. doi:10.1016/j.thromres.2011.01.005.CrossRefPubMed

45.

Li C, Raikwar NS, Santillan MK, Santillan DA, Thomas CP. Aspirin inhibits expression of sFLT1 from human cytotrophoblasts induced by hypoxia, via cyclo-oxygenase 1. Placenta. 2015;36:446–53. doi:10.1016/j.placenta.2015.01.004.CrossRefPubMedPubMedCentral

46.

Vieillefosse S, Guibourdenche J, Atallah A, Haddad B, Fournier T, Tsatsaris V, et al. Predictive and prognostic factors of preeclampsia: interest of PlGF and sFLT-1. J Gynecol Obstet Biol Reprod (Paris). 2016;45:999–1008. doi:10.1016/j.jgyn.2016.02.006.CrossRef

47.

Tsatsaris V, Goffin F, Munaut C, Brichant J-F, Pignon M-R, Noel A, et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab. 2003;88:5555–63. doi:10.1210/jc.2003-030528.CrossRefPubMed

48.

Craven LL. Prevention of coronary and cerebral thrombosis. Miss Val Med J Quincy Ill. 1956;78:213–5.

49.

Beaufils M, Donsimoni R, Uzan S, Colau JC. Prevention of pre-eclampsia by early antiplatelet therapy. The Lancet. 1985;325:840–2. doi:10.1016/S0140-6736(85)92207-X.CrossRef

50.

Uzan S, Beaufils M, Breart G, Uzan S, Bazin B, Capitant C, et al. Originally published as Volume 1, Issue 8755Prevention of fetal growth retardation with low-dose aspirin: findings of the EPREDA trial. The Lancet. 1991;337:1427–31. doi:10.1016/0140-6736(91)93124-R.CrossRef

51.

Anonymous. CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. Lancet. 1994;343(8898):619–29.

52.

Caritis S, Sibai B, Hauth J, Lindheimer MD, Klebanoff M, Thom E, et al. Low-dose aspirin to prevent preeclampsia in women at high risk. N Engl J Med. 1998;338:701–5. doi:10.1056/NEJM199803123381101.CrossRefPubMed

53.

Duley L, Henderson-Smart D, Knight M, King J. Antiplatelet drugs for prevention of pre-eclampsia and its consequences: systematic review. BMJ. 2001;322:329–33.CrossRefPubMedPubMedCentral

54.

Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. In: The Cochrane Collaboration (ed). Cochrane Database Syst. Rev. Wiley, Chichester; 2007.

55.

Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol. 2010;116:402–14. doi:10.1097/AOG.0b013e3181e9322a.CrossRefPubMed

56.

Meher S, Duley L, Hunter K, Askie L. Antiplatelet therapy before or after 16 weeks’ gestation for preventing preeclampsia: an individual participant data meta-analysis. Am J Obstet Gynecol. 2017;216(121–128):e2. doi:10.1016/j.ajog.2016.10.016.

57.

Henderson JT, Whitlock EP, O’Conner E, Senger CA, Thompson JH, Rowland MG. Low-dose aspirin for the prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive services task force. Rockville (MD): Agency for Healthcare Research and Quality (US); 2014.

58.

ACOG Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol. 2002;99:159–67.CrossRef

59.

Werner EF, Hauspurg AK, Rouse DJ. A cost-benefit analysis of low-dose aspirin prophylaxis for the prevention of preeclampsia in the United States. Obstet Gynecol. 2015;126:1242–50.CrossRefPubMed

60.

Sibai BM. Therapy: low-dose aspirin to reduce the risk of pre-eclampsia? Nat Rev Endocrinol. 2015;11:6–8. doi:10.1038/nrendo.2014.199.CrossRefPubMed

61.

MOUNIER-VEHIER C. Consensus d’Experts de la Société Française d’Hypertension Artérielle 2015. http://www.sfhta.eu/wp-content/uploads/2015/11/Recommandations_HTA_et_grossesse_dec_2015202.pdf. Accessed 19 June 2016.

62.

Henderson JT, Whitlock EP, O’Connor E, Senger CA, Thompson JH, Rowland MG. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2014;160:695–703. doi:10.7326/M13-2844.CrossRefPubMed

63.

Practice Advisory on Low-Dose Aspirin and Prevention of Preeclampsia: Updated Recommendations—ACOG n.d. http://www.acog.org/About-ACOG/News-Room/Practice-Advisories/Practice-Advisory-Low-Dose-Aspirin-and-Prevention-of-Preeclampsia-Updated-Recommendations. Accessed 20 Apr 2017.

64.

Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary n.d. https://sogc.org/wp-content/uploads/2014/05/gui307CPG1405Erev.pdf.

65.

Hypertension in pregnancy: diagnosis and management | Guidance and guidelines | NICE n.d. https://www.nice.org.uk/guidance/CG107. Accessed 20 Apr 2017.

66.

Guidance regarding the use of low-dose aspirin in the prevention of pre-eclampsia in high-risk women. n.d. https://www.midwife.org.nz/.

67.

Krieger VI, Weiden S. The value of the cold pressor test in the prediction of hypertension and toxaemia in pregnancy. Med J Aust. 1947;1:417–23.PubMed

68.

Parra-Cordero M, Turan OM, Kaur A, Pearson JD, Nicolaides KH. Maternal serum soluble adhesion molecule levels at 11 + 0-13 + 6 weeks and subsequent development of pre-eclampsia. J Matern-Fetal Neonatal Med Off J Eur Assoc Perinat Med Fed Asia Ocean Perinat Soc Int Soc Perinat Obstet. 2007;20:793–6. doi:10.1080/14767050701500349.

69.

Caradeux J, Serra R, Nien J-K, Pérez-Sepulveda A, Schepeler M, Guerra F, et al. First trimester prediction of early onset preeclampsia using demographic, clinical, and sonographic data: a cohort study. Prenat Diagn. 2013;33:732–6. doi:10.1002/pd.4113.CrossRefPubMed

70.

Scazzocchio E, Figueras F, Crispi F, Meler E, Masoller N, Mula R, et al. Performance of a first-trimester screening of preeclampsia in a routine care low-risk setting. Am J Obstet Gynecol. 2013;208:203.e1–10. doi:10.1016/j.ajog.2012.12.016.CrossRef

71.

Odibo AO, Patel KR, Spitalnik A, Odibo L, Huettner P. Placental pathology, first-trimester biomarkers and adverse pregnancy outcomes. J Perinatol Off J Calif Perinat Assoc. 2014;34:186–91. doi:10.1038/jp.2013.176.CrossRef

72.

Parra-Cordero M, Rodrigo R, Barja P, Bosco C, Rencoret G, Sepúlveda-Martinez A, et al. Prediction of early and late pre-eclampsia from maternal characteristics, uterine artery Doppler and markers of vasculogenesis during first trimester of pregnancy. Ultrasound Obstet Gynecol Off J Int Soc Ultrasound Obstet Gynecol. 2013;41:538–44. doi:10.1002/uog.12264.CrossRef

73.

Plasencia W, Maiz N, Bonino S, Kaihura C, Nicolaides KH. Uterine artery Doppler at 11 + 0 to 13 + 6 weeks in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol. 2007;30:742–9. doi:10.1002/uog.5157.CrossRefPubMed

74.

Villa PM, Kajantie E, Räikkönen K, Pesonen A-K, Hämäläinen E, Vainio M, et al. Aspirin in the prevention of pre-eclampsia in high-risk women: a randomised placebo-controlled PREDO Trial and a meta-analysis of randomised trials. BJOG Int J Obstet Gynaecol. 2013;120:64–74. doi:10.1111/j.1471-0528.2012.03493.x.CrossRef

75.

Poon LCY, Kametas NA, Maiz N, Akolekar R, Nicolaides KH. First-trimester prediction of hypertensive disorders in pregnancy. Hypertens Dallas Tex. 1979;2009(53):812–8. doi:10.1161/HYPERTENSIONAHA.108.127977.

76.

Oliveira N, Doyle LE, Atlas RO, Jenkins CB, Blitzer MG, Baschat AA. External validity of first-trimester algorithms in the prediction of pre-eclampsia disease severity. Ultrasound Obstet Gynecol Off J Int Soc Ultrasound Obstet Gynecol. 2014;44:286–92. doi:10.1002/uog.13433.CrossRef

77.

Oliveira N, Magder LS, Blitzer MG, Baschat AA. First-trimester prediction of pre-eclampsia: external validity of algorithms in a prospectively enrolled cohort. Ultrasound Obstet Gynecol Off J Int Soc Ultrasound Obstet Gynecol. 2014;44:279–85. doi:10.1002/uog.13435.CrossRef

78.

O’Gorman N, Wright D, Syngelaki A, Akolekar R, Wright A, Poon LC, et al. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation. Am J Obstet Gynecol. 2016;214:103.e1–12. doi:10.1016/j.ajog.2015.08.034.CrossRef

79.

Rolnik D, Wright D, Poon L, O’Gorman N, Syngelaki A, de Paco Matallana C, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;. doi:10.1056/NEJMoa1704559.PubMed

80.

Roberge S, Nicolaides KH, Desmers S, Hyett J, Chaillet N, Bujold E. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol. 2017;216(110–120):e6.

81.

Tan M, Koutoulas L, Wright D, Nicolaides KH, Poon L. A study protocol for the prospective validation study: screening programme for pre-eclampsia (SPREE). Ultrasound Obstet Gynecol. 2017;. doi:10.1002/uog.17467.

82.

Rolnik DL, Wright D, Poon LCY, Syngelaki A, O’Gorman N, de Paco Matallana C, et al. ASPRE trial: performance of screening for preterm pre-eclampsia. Ultrasound Obstet Gynecol Off J Int Soc Ultrasound Obstet Gynecol. 2017;. doi:10.1002/uog.18816.

83.

Mahmoud AN, Elgendy AY, Rambarat C, Mahtta D, Elgendy IY, Bavry AA. Efficacy and safety of aspirin in patients with peripheral vascular disease: an updated systematic review and meta-analysis of randomized controlled trials. PLoS One. 2017;12:e0175283. doi:10.1371/journal.pone.0175283.CrossRefPubMedPubMedCentral

84.

Chen W-C, Lin K-H, Huang Y-T, Tsai T-J, Sun W-C, Chuah S-K, et al. The risk of lower gastrointestinal bleeding in low-dose aspirin users. Aliment Pharmacol Ther. 2017;. doi:10.1111/apt.14079.

85.

Benito-Garcia E, Michaud K, Wolfe F. The effect of low-dose aspirin on the decreased risk of development of dyspepsia and gastrointestinal ulcers associated to cyclooxygenase-2 selective inhibitors. J Rheumatol. 2007;34:1765–9.PubMed

86.

Belcon MC, Rooney PJ, Tugwell P. Aspirin and gastrointestinal haemorrhage: a methodologic assessment. J Chronic Dis. 1985;38:101–11.CrossRefPubMed

87.

Stevenson DD, White AA, Simon RA. Aspirin as a cause of pancreatitis in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2012;129:1687–8. doi:10.1016/j.jaci.2012.04.016.CrossRefPubMed

88.

Kennedy JL, Stoner AN, Borish L. Aspirin-exacerbated respiratory disease: prevalence, diagnosis, treatment, and considerations for the future. Am J Rhinol Allergy. 2016;30:407–13. doi:10.2500/ajra.2016.30.4370.CrossRefPubMedPubMedCentral

89.

Lei H, Gao Q, Liu S-R, Xu J. The benefit and safety of aspirin for primary prevention of ischemic stroke: a meta-analysis of randomized trials. Front Pharmacol. 2016;7:440. doi:10.3389/fphar.2016.00440.CrossRefPubMedPubMedCentral

90.

Leonhardt A, Bernert S, Watzer B, Schmitz-Ziegler G, Seyberth HW. Low-dose aspirin in pregnancy: maternal and neonatal aspirin concentrations and neonatal prostanoid formation. Pediatrics. 2003;111:e77–81. doi:10.1542/peds.111.1.e77.CrossRefPubMed

91.

Jacobson RL, Brewer A, Eis A, Siddiqi TA, Myatt L. Transfer of aspirin across the perfused human placental cotyledon. Am J Obstet Gynecol. 1991;165:939–44.CrossRefPubMed

92.

Hertz-Picciotto I, Hopenhayn-Rich C, Golub M, Hooper K. The risks and benefits of taking aspirin during pregnancy. Epidemiol Rev. 1990;12:108–48.CrossRefPubMed

93.

Slone D, Siskind V, Heinonen OP, Monson RR, Kaufman DW, Shapiro S. Aspirin and congenital malformations. Lancet Lond Engl. 1976;1:1373–5.CrossRef

94.

Klebanoff MA, Berendes HW. Aspirin exposure during the first 20 weeks of gestation and IQ at four years of age. Teratology. 1988;37:249–55. doi:10.1002/tera.1420370310.CrossRefPubMed

95.

Werler MM, Mitchell AA, Shapiro S. The relation of aspirin use during the first trimester of pregnancy to congenital cardiac defects. N Engl J Med. 1989;321:1639–42. doi:10.1056/NEJM198912143212404.CrossRefPubMed

96.

Nørgård B, Puhó E, Czeizel AE, Skriver MV, Sørensen HT. Aspirin use during early pregnancy and the risk of congenital abnormalities: a population-based case-control study. Am J Obstet Gynecol. 2005;192:922–3. doi:10.1016/j.ajog.2004.10.598.CrossRefPubMed

97.

Sasidharan CK, Kutty PM, Ajithkumar, Sajith N. Fetal intracranial hemorrhage due to antenatal low dose aspirin intake. Indian J Pediatr. 2001;68(11):1071–2.

98.

Rotchell YE, Cruickshank JK, Gay MP, Griffiths J, Stewart A, Farrell B, et al. Barbados Low Dose Aspirin Study in Pregnancy (BLASP): a randomised trial for the prevention of pre-eclampsia and its complications. Br J Obstet Gynaecol. 1998;105:286–92.CrossRefPubMed

99.

Di Sessa TG, Moretti ML, Khoury A, Pulliam DA, Arheart KL, Sibai BM. Cardiac function in fetuses and newborns exposed to low-dose aspirin during pregnancy. Am J Obstet Gynecol. 1994;171:892–900.CrossRefPubMed

100.

Schiessl B, Schneider KT, Zimmermann A, Kainer F, Friese K, Oberhoffer R. Prenatal constriction of the fetal ductus arteriosus–related to maternal pain medication? Z Geburtshilfe Neonatol. 2005;209:65–8. doi:10.1055/s-2005-864116.CrossRefPubMed

101.

Wyatt-Ashmead J. Antenatal closure of the ductus arteriosus and hydrops fetalis. Pediatr Dev Pathol Off J Soc Pediatr Pathol Paediatr Pathol Soc. 2011;14:469–74. doi:10.2350/07-11-0368.1.CrossRef

Title: Aspirin for Prevention of Preeclampsia
Authors: A. Atallah
E. Lecarpentier
F. Goffinet
M. Doret-Dion
P. Gaucherand
V. Tsatsaris
Publication date: 01-11-2017
Publisher: Springer International Publishing
Published in: Drugs / Issue 17/2017
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-017-0823-0

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Aspirin for Prevention of Preeclampsia

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 17/2017

A Review of Food–Drug Interactions on Oral Drug Absorption

Ciclosporin Ophthalmic Emulsion 0.1%: A Review in Severe Dry Eye Disease

Tivozanib: First Global Approval

Authors’ Reply to Yilmaz and Türk: “Targeting the PGD2/CRTH2/DP1 Signaling Pathway in Asthma and Allergic Disease: Current Status and Future Perspectives”

Tocilizumab: A Review in Rheumatoid Arthritis

Comment on: “Targeting the PGD2/CRTH2/DP1 Signaling Pathway in Asthma and Allergic Disease: Current Status and Future Perspectives”